Covishield, India’s first COVID-19 vaccine is authorised and is secure, efficient and prepared for roll-out: SII CEO

New Delhi: Serum Institute of India Chief Executive Officer Adar Poonawalla on Sunday stated that Covishield, India’s first COVID-19 vaccine is authorised and is secure, efficient and prepared for roll-out within the coming weeks.
Taking to Twitter, Poonawalla stated, “Happy new year, everyone! All the risks @SerumInstIndia took with stockpiling the vaccine have finally paid off. COVISHIELD, India’s first COVID-19 vaccine is approved, safe, effective, and ready to roll-out in the coming weeks.”

Happy new yr, everybody! All the dangers @SerumInstIndia took with stockpiling the vaccine, have lastly paid off. COVISHIELD, India’s first COVID-19 vaccine is authorised, secure, efficient and able to roll-out within the coming weeks. pic.twitter.com/TcKh4bZIKK
— Adar Poonawalla (@adarpoonawalla) January 3, 2021

He additionally thanked the political management, together with Prime Minister Narendra Modi, Union Health Minister Dr Harsh Vardhan and Drugs Controller General of India (DCGI).
“Thank you Hon. Sri @narendramodi Ji, Hon. Sri @drharshvardhan Ji, @MoHFW_INDIA @ICMRDELHI
@DBTIndia #[email protected] @AstraZeneca @gavi @GaviSeth @gatesfoundation and @BillGates in your assist, @drharshvardhan ji, thanks for launching PNEUMONSIL, manufactured by @SerumInstIndia, the primary made-in-India vaccine to forestall the illness of Pneumonia in kids. Thank you @MoHFW_INDIA @gatesfoundation @PATHtweets and particularly @BillGates,” he tweeted.

Thank you Hon. Sri @narendramodi Ji, Hon. Sri @drharshvardhan Ji, @MoHFW_INDIA @ICMRDELHI @DBTIndia #DCGI_India @UniofOxford @AstraZeneca @gavi @GaviSeth @gatesfoundation and @BillGates in your assist
— Adar Poonawalla (@adarpoonawalla) January 3, 2021

He additionally thanked Bill and Melinda Gates Foundation.
Earlier in the present day, COVID-19 vaccines of Serum Institue of India and Bharat Biotech have been granted permission for restricted use in an emergency state of affairs, stated Drugs Controller General of India (DCGI).
“After adequate examination, CDSCO has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situation and permission is being granted to M/s Cadila Healthcare for conduct of the Phase III clinical trial,” stated VG Somani, DCGI, throughout a media briefing in the present day.